论文部分内容阅读
现已知我国半数地区间时存在着姬鼠和家鼠二种型别的肾综合征出血热(HFRS)的混合流行,因此,有必要研制能同时预防这二种型别的疫苗。目前我国用于生产疫苗的三株HFRS病毒,对同型各毒株均表现较好的中和作用,但对异型病毒的交叉中和作用较差。经人体免疫三针后,对同型病毒的中和抗体阳转率可达90%,而对异型病毒的阳转率仅30%左右。因而,在我国,研制双价HFRS疫苗的工作早已被提出来了。本文报道我们研制的双价HFRS沙鼠肾灭活疫苗免疫人体的结果。材料与方法一、疫苗:由杭州天元生物药业公司生产的双价肾综合征出血热沙鼠肾细胞灭活疫苗(批号双-4),制造疫苗的毒种为Z10(Ⅰ型)和Z37(Ⅱ型),病毒在沙鼠肾原代细胞培养后,经β-丙内脂灭活,内含0.1%人血白蛋白和0.5mg/ml氢氧化铝佐剂,先分别制成Ⅰ型和Ⅱ型的单价疫苗,再按不同比例混合而成双价疫苗。
It is known that there is a mixed epidemic of two types of Apodemus aguascteri and Hemoglobin (HFRS) in half of China’s regions. Therefore, it is necessary to develop a vaccine that can prevent both types of HFRS. At present, the three HFRS viruses that are used for vaccine production in our country show good neutralization effect on all strains of the same type, but they have poor cross-neutralization effect on heterotypic viruses. After three doses of human immunization, the positive rate of neutralizing antibody to the same virus can reach 90%, while the positive rate of heterotypic virus is only about 30%. Therefore, in our country, the work of developing a dual-price HFRS vaccine has already been put forward. This article reports the results of the human immunization of the dual-dose HFRS gerbil-nephropathy inactivated vaccine. MATERIALS AND METHODS A. Vaccine: Hemorrhagic fever gerbil kidney cell inactivated vaccine (batch number double-4) produced by Hangzhou Tianyuan Bio-pharmaceutical Co., Ltd. was used to produce the vaccine strain Z10 (type I) and Z37 (Type II). The virus was inactivated by β-propiolactone in gerbil kidney primary cells and contained 0.1% human serum albumin and 0.5 mg / ml aluminum hydroxide adjuvant. And type II monovalent vaccine, and then mixed into a different ratio of bivalent vaccine.